On Friday, Opko Health Inc. (NYSE:OPK)’s shares declined -0.06% to $16.55.
Opko Health Inc. (OPK) may fit the first condition of being at or near its highs, but it does not fulfill the second. Those short Opko don’t seem to mind all that much, being that 44.92M shares are presently held short, constituting 67% of the float. That’s about a million more shares than last month, representing over $15M in capital spent on shorting the stock in one month, at least.
While shorting itself may tend to discourage some retail investors from taking a position, institutional investors in addition to company insiders are usually astute enough to know that for every short seller, there is a buyer of those shares on the other side. Close to 70% of Opko’s float is held by either insiders or institutions, and it is doubtful that any of those shares will be put on the open market any time soon. And even if some are, the company’s founder and CEO, Dr. Phillip Frost, is picking shares at the same pace that shortsellers are borrowing them to sell.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, counting point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products comprise 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins.
McGraw Hill Financial Inc (NYSE:MHFI)’s shares gained 2.25% to $103.16.
A division of McGraw Hill Financial (MHFI), The outlook for steel prices in China slumped to a six-month low, while expectations for domestic orders during July also deteriorated, according to the latest Platts China Steel Sentiment Index (Platts CSSI) for July, which showed a headline reading of 26.5 out of a possible 100 points.
The July index fell 15.7 points from the June level of 42.2 and was the weakest reading since the Chinese New Year holiday period in February. The outlook for prices of both long- and flat-steel products dropped below the 50 threshold following three successive months of stronger expectations. The outlook for new domestic steel orders showed a large drop for the second successive month, to 26.4 from 43.2 in June; while export order expectations were almost flat on the previous month at 28.3.
McGraw Hill Financial, Inc. provides benchmarks and ratings, analytics, data, and research services for the capital, commodities, and commercial markets worldwide. It operates in four segments: Standard & Poor’s Ratings Services (S&P Ratings), S&P Capital IQ, S&P Dow Jones Indices (S&P DJ Indices), and Commodities & Commercial (C&C). The S&P Ratings segment provides credit ratings, research, and analytics to the investors, corporations, governments, municipalities, commercial and investment banks, insurance companies, asset managers, and other debt issuers.
At the end of Friday’s trade, Tenaris SA (ADR) (NYSE:TS)‘s shares surged 2.30% to $25.81.
Tenaris SA (ADR) (TS) declares that, following the formerly declared restatement of its quarterly merged financial statements as of September 30, 2014, its annual merged financial statements as of December 31, 2014, and its quarterly merged financial statements as of March 31, 2015, to reflect a lower carrying value of its investments in Usiminas, it has filed with the U.S. Securities and Exchange Commission (SEC) its annual report on Form 20-F for the year ended December 31, 2014, and has presented to the SEC its restated quarterly and annual financial statements. As a consequence of the restatement of the merged financial statements as of December 31, 2014, the Company has also filed with the Luxembourg Stock Exchange a restated annual report on the merged financial statements for the year ended December 31, 2014, prepared in accordance with applicable Luxembourg law requirements, and has presented such restated annual report to the other securities regulators of the markets where its securities are listed.
Tenaris S.A., through its auxiliaries, manufactures and supplies steel pipe products and related services for the energy and other industrial applications. It offers products for oil and gas drilling operations that comprise casings and tubings, premium connections, drill pipes, coiled tubing, hot-rolled and cold-drawn tubes, tubular and non-tubular accessories, and devices, in addition to technical consulting, pipe administration, and field services
MannKind Corporation (NASDAQ:MNKD), ended its Friday’s trading session with 4.87% gain, and closed at $5.38.
MannKind Corporation (MNKD), a leading biopharmaceutical company focused on patient experience, acknowledged today that Executive Chairman Alfred Mann was honored last night at a gala for his extensive work in the progression and advancement of diabetes technologies and advocacy.
Held in conjunction with the 75th annual American Diabetes Association Scientific Sessions in Boston, the reception was co-hosted by Kelly L. Close, leading diabetes advocate and founder of the diaTribe Foundation, along with Dr. Steven Edelman, nationally recognized endocrinologist and founder of Take Control of Your Diabetes (TCOYD). In addition to last night’s honors, Mr. Mann was also recently awarded the JDRF’s Lifetime Achievement Award, one of the leading awards in diabetes internationally.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
